Navigation Links
Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2009 Financial Results
Date:5/15/2009

    CHENGDU, China, May 15 /PRNewswire-Asia-FirstCall/ --

    - Third Quarter 2009 Revenue Increased 7.4% to $9.9 Million while Net
      Income Increased 48.8% to $1.9 Million with EPS of $0.10
    - Revenue for the First Nine Months Increased 22.4 % to $29.6 Million, Net
      Income Increased 29.2% to $5.7 Million with EPS of $0.23
    - Cash and Equivalents of $10.7 Million on March 31, 2009
    - Cash Flow from Operations Increased 150.6% to $4.4 million for the First
      Nine Months of Fiscal 2009
    - Received Ten New Approvals from the SFDA during the First 9 Months of
      Fiscal 2009
    - New Production Facility to Commence Operations this Summer Increasing
      Capacity for Solid Dose Drugs by 300%

Tianyin Pharmaceutical Co., Inc., (NYSE Alternext: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced fiscal results for its third quarter ended March 31, 2009.

Revenue for the third quarter of 2009 increased 7.4% to approximately $9.9 million compared to $9.2 million for the third quarter of 2008. The slowdown in year-over-year growth was due to capacity production constraints and longer lead times into the distribution channels as new drugs were commercialized.

Cost of goods sold for the three months ended March 31, 2009 was approximately $5.1 million or 51.1% of revenue as compared to $5.1 million or 55.4% of revenue for the three months ended March 31, 2008, yielding a gross profit of $4.9 million and gross margins of 48.9%, compared to $4.1 million in gross profit and a margins of 44.6% during the third quarter of fiscal 2008. Thus, gross profits grew by 17.8% on a year-over-year basis as a result of higher sales, while margins improved through the optimization of product portfolio and enhanced cost controls implemented during the manufacturing process.

Operating expenses for the three months ended March 31, 2009 were approximately $2.6 million, up 13.1% compared to the same period in 2008. Selling, general and administration expenses for the period increased to approximately $2.5 million from $2.2 million in the third quarter of 2008 as a result of the implementation of Tianyin's sales and marketing strategy, including increased sales payrolls and direct marketing expenses. Research and development expenses were nearly flat at $0.1 million for the three months ended March 31, 2009 compared to the year ago period.

Operating income for the third quarter of 2009 totaled approximately $2.3 million, a 23.5% increase from the $1.9 million reported for the third quarter of 2008. Operating margins were 23.1% and 20.1% for the third quarter of fiscal 2009 and fiscal 2008, respectively and were the result of increased revenues and gross profit, along with the prudent management of operating expenses.

Net income was approximately $1.9 million in the third quarter of fiscal 2009, a 48.8% increase, compared to $1.3 million for the third quarter of 2008. The company had an effective tax rate of 16.7% and 20.9%, for the third quarter of fiscal 2009 and 2008, respectively. Diluted earnings per share were $0.10 compared to $0.05 for the third quarter of fiscal 2009 and fiscal 2008 respectively, based upon 16 million and 24.5 million shares. The divergence in the share account relates to accounting for the company's preferred shares which are convertible into common.

Nine Month Results

For the nine months ended March 31, 2009, revenues increased approximately 22.4% to $29.6 million compared to the same period in 2008. Gross profit was $14.9 million for the first nine months of 2009, representing an increase of 46.3% from the first nine months of 2008. Gross margins were 50.3% for the first nine months of 2009 compared to 42.1% for the same period in 2008.

Income from operations was $6.9 million for the first nine months of 2009, representing an increase of 22.7% over the first nine months of 2008. Operating margins were at 23.4% for both nine month periods, respectively. Net income was $5.7 million for the nine months ended March 31, 2009, an increase of 29.2% from the same period in 2008. Diluted earnings per share were $0.23 compared to $0.27 for the first nine months of 2009 and 2008 respectively, based up on 25 million and 16.7 million shares.

"We are pleased to report another quarter of revenue growth and improved profitability. While revenue growth was impacted by capacity constraints, we are very enthusiastic about the launch of our new production facility which is expected to be online during the summer of 2009," commented Dr. Guoqing Jiang, Tianyin's Chief Executive Officer. "The Chinese government recently announced that it will significantly increase the overall investment in the Traditional Chinese Medicine (TCM) sector while implementing favorable policies to accelerate the development of new drugs, which we believe will provide a solid foundation for sustained future growth. Companies like Tianyin will be a beneficiary of this enhanced government support, which includes China's $123 billion health care reform plan focused on bringing a broader spectrum of services and pharmaceutical products to all Chinese residents. We are confident that our extensive product portfolio and drug pipeline, proven sales and marketing capabilities, and committed management team will enable us to accelerate our growth and capitalize on a long-term, secular growth opportunity."

Balance Sheet and Cash Flow

Cash and cash equivalents and restricted cash totaled $10.7 million on March 31, 2009 compared to $12.1 million on June 30, 2008. The Company had a current ratio of 5.8 to 1 and stockholders' equity of 39.2 million, with total assets of $42.9 million versus total liabilities of $3.8 million on March 31, 2009. For the first nine months of 2009, the Company generated $4.4 million in cash from operations versus $1.8 million for the same period in 2008.

Business Development

On January 30, 2009, Tianyin began initial purchases under its previously announced stock repurchase program to buy back up to $3.0 million of its common stock. These shares will be retired to the treasury while reducing the number of outstanding common shares. As of March 31, 2009, 79,285 shares have been bought back at prevailing market prices.

During the third quarter of fiscal 2009, Tianyin adopted the "Cost Preference Strategy" for Azithromycin Dispersible Tablets which could yield over $3.7 million in incremental revenues on an annual basis in the future.

On March 26, 2009, Tianyin announced that the Board of Directors declared an annual cash dividend of $0.10 per common share that will be paid quarterly. On April 14, the majority of the Company's Series A Preferred Shareholders approved the cash dividend to common stockholders. The initial dividend of $.025 will be paid to common shareholders of record on April 30, 2009, with the actual distribution occurring on or about June 10, 2009. The decision was made so the company could provide its common shareholders with ongoing participation in company profits while ensuring that adequate capital was available for future growth.

During the quarter, Tianyin completed installing the steel framework and roofing of the new production facility with production expected to commence in the summer of 2009. The Company recently completed the construction and began testing its production line recently. The new plant will expand production capacity of solid dosage drugs by 300% and will be utilized to meet growing demand for the Company's current products, while also accommodating new product launches for those in the development pipeline.

During the first nine months of fiscal 2009, Tianyin received ten new approvals from the SFDA to produce Laonian Kechuan Tablet (SFDA approval number H2008S02059), Fuke Zhidai Tablet (SFDA approval number Z20083375), Tongbianling Capsule (SFDA approval number Z20083424), Baotailing Tablets (SFDA approval numberZ20093087), Duyiwei Dispersible Tablets (SFDA approval number Z20090239), Compound Dantong Capsules (SFDA approval number Z20093012), Mycophenolate Mofetil Capsule(SFDA approval number H20080819), Tongqiao Biyan Tablets(SFDA approval number Z20093063), Child Qingrezhike Oral Liquid(SFDA approval number Z20093060), Yiqing Capsules(SFDA approval number Z20093084). In addition, Tianyin currently has 17 drug candidates under the Chinese State Food and Drug Administration (SFDA) review.

"We are making progress on all aspects of our business. We have completed construction of the new production facility and are in the testing production phase. As of today, we have successfully tested most equipment and anticipate finishing this phase by the end of May 2009. The tripled capacity of solid dosage drugs will accommodate increasing production volumes and expected future growth. In addition, we received ten approvals from the Chinese State Food and Drug Administration (SFDA) during the first nine months of fiscal 2009. The increased production capacity and new additions to our production portfolio, along with other initiatives, have set a foundation for long-term growth and profitability of our business. We will continue to execute our growth plan and maximize value for our shareholders," concluded Dr. Jiang.

Business Outlook

Management is confirming fiscal 2009 guidance for the year which ends June 30 and expects to report revenues of more than $46 million and net income of at least $7.5 million, representing 37.3% and 25% year over year growth respectively.

Conference Call

The Company will host a conference call to discuss the 2009 third quarter financial results on Friday, May 15, 2009 at 11:00 a.m. EDT. Interested participants should call +1-877-941-2927 within the United States, or US +1-480-629-9725 if calling internationally. The conference ID is 4076664. It is advisable to dial in approximately 5-10 minutes prior to 11:00 a.m. EDT. If you are unable to participate in the call at the scheduled time, a playback will be available through May 29, 2009. To listen to the playback, please call +1-800-406-7325 from within the United States, or US +1-303-590-3030 internationally. Please use passcode 4076664 for the replay.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 39 products, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 40 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. Tianyin achieved revenue of approximately $33.5 million and net income of approximately $6 million in FY2008 ending June 30, 2008. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

    For the Company:
     Allen Tang, Ph.D., MBA, Assistant to the CEO
     China
     Tel:   +86-158-2122-5642
     Email: Allen.y.tang@gmail.com

    Investors:
     Mr. Matthew Hayden, HC International
     Tel:   +1-561-245-5155
     Email: matt.hayden@hcinternational.net
     Web:  http://www.hcinternational.net



                           Consolidated Balance Sheets

                                               March 31,         June 30,
                                                 2009              2008
                                             (Unaudited)
    Assets:
    Current assets:
      Cash and cash equivalents              $10,733,671       $12,057,150
      Accounts receivable, net of allowance
       for doubtful accounts of $90,435 and
       $90,064 at March 31, 2009 and June 30,
       2008, respectively                      4,991,353         4,460,406
      Inventory                                4,666,509         3,555,691
      Advance payments                         1,188,115                --
      Other receivables                          415,849           371,815
      Other current assets                            --           247,139
        Total current assets:                 21,995,497        20,692,201

    Property and equipment, net:               8,292,735         5,758,966

    Intangibles, net:                         12,646,750        10,307,754

                Total assets:                $42,934,982       $36,758,921

    Liabilities and stockholders' equity:
    Current liabilities:
      Accounts payable and accrued expenses   $1,266,619        $1,337,682
      Short-term bank loans                    1,399,075         1,393,345
      VAT taxes payable                          324,311           277,090
      Income taxes payable                       380,546           341,214
      Payroll taxes payable                        9,007            39,939
      Dividends payable                               --           378,545
      Other current liabilities                  391,272           142,733
        Total current liabilities:             3,770,830         3,910,548
        Total liabilities:                     3,770,830         3,910,548

    Stockholders' equity:
      Common stock, $0.001 par value,
       50,000,000 shares authorized,
       16,064,428 and 14,738,450 shares
       issued and outstanding at March 31,
       2009 and June 30, 2008                     16,064            14,739
      Common stock dividend distributable            217                --
      Series A convertible preferred stock,
       $0.001 par value, 8,744,375 and
       9,384,375 shares issued and
       outstanding at March 31, 2009
       and June 30, 2008                           8,744             9,384
      Additional paid-in capital              19,445,520        18,002,439
      Statutory reserve                        2,031,451         1,380,806
      Treasury stock                            (102,737)               --
      Retained earnings                       14,991,010        10,963,131
      Accumulated other comprehensive
       income                                  2,773,883         2,477,874
        Total stockholders' equity:           39,164,152        32,848,373
        Total liabilities and
         stockholders' equity:               $42,934,982       $36,758,921



          Consolidated Statements of Operations and Comprehensive Income
                                     (Unaudited)

                           For the Three Months Ended   For the Nine Months
                                                               Ended
                                    March 31,                March 31,
                                2009        2008         2009        2008

    Sales:                   $9,929,301  $9,249,229  $29,593,109  $24,167,921

    Cost of sales:            5,069,133   5,123,587   14,696,736   13,984,845

    Gross profit:             4,860,168   4,125,642   14,896,373   10,183,076

    Operating expenses:
      Selling, general and
       administrative         2,481,188   2,180,161    7,709,861    4,380,702
      Research and
       development               86,495      89,372      253,353      150,930

        Total operating
         expenses:            2,567,683   2,269,533    7,963,214    4,531,632

    Income from operations:   2,292,485   1,856,109    6,933,159    5,651,444

    Other income (expenses):
      Other income                4,874          --       34,682           --
      Interest expense          (20,821)   (245,174)     (75,515)    (311,536)
        Total other income
         (expenses):            (15,947)   (245,174)     (40,833)    (311,536)

    Income before provision
     for income tax:          2,276,538   1,610,935    6,892,326    5,339,908

    Provision for income tax:   380,521     337,132    1,148,197      893,779

    Net income:               1,896,017   1,273,803    5,744,129    4,446,129

    Other comprehensive
     income (loss):
      Foreign currency
       translation
       adjustment               (50,359)    793,507      296,009    1,368,473

    Comprehensive income:    $1,845,658  $2,067,310   $6,040,138   $5,814,602

    Basic earnings per share:     $0.10       $0.09        $0.29        $0.33

    Diluted earnings per share:   $0.10       $0.05        $0.23        $0.27

    Weighted average number
     of common shares
     outstanding:
        Basic                15,987,334  14,274,783   15,902,618   13,289,072
        Diluted              15,987,334  24,455,363   24,980,236   16,707,369




                   Consolidated Statements of Cash Flows
                                 (Unaudited)


                                                  For the Nine Months Ended
                                                           March 31,
                                                     2009            2008
    Cash flows from operating activities:
      Net Income                                  $5,744,129      $4,446,129
      Adjustments to reconcile net income to
       net cash provided by (used in) operating
       activities:
      Depreciation and amortization                  355,933         273,060
      Changes in current assets and
       current liabilities:
        Accounts receivable                         (512,429)       (535,631)
        Inventory                                 (1,095,822)       (550,711)
        Other receivables                            628,103          89,183
        Other current assets                        (940,570)     (2,005,616)
        Accounts payable and accrued expenses        (76,119)        (13,158)
        VAT taxes payable                             46,066           9,280
        Income taxes payable                          37,915          13,565
        Payroll taxes payable                        (31,085)          4,254
        Other current liabilities                    247,867          26,753
                Total adjustments:                (1,340,141)     (2,689,021)

                Net cash provided by
                 operating activities:             4,403,988       1,757,108

    Cash flows from investing activities:
      Additions to property and equipment            (57,994)       (276,472)
      Additions to intangibles                    (2,416,425)       (786,712)
      Additions to construction in progress       (2,686,567)             --

                Net cash used in investing
                 activities:                      (5,160,986)     (1,063,184)

    Cash flows from financing activities:
      Proceeds from capital contribution                  --       9,089,700
      Proceeds from (repayment of) bank loans       (512,575)      2,674,873
      Repayment of shareholder loans                (102,737)       (143,967)

                Net cash provided by (used
                 in) financing activities:          (615,312)     11,620,606

    Effect of foreign currency translation
     on cash:                                         48,831         685,138

    Net increase (decrease) in cash and
     cash equivalents:                            (1,323,479)     12,999,668

    Cash and cash equivalents - beginning:        12,057,150         624,390

    Cash and cash equivalents - ending:          $10,733,671     $13,624,058


'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker OTC BB: TYNP
2. Tianyin Pharmaceutical to Present at Roth Third Annual China Discovery Tour in Beijing on May 20, 2008 at 12:40 p.m. Beijing Time
3. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2008 Third Quarter Earnings Conference Call on Thursday, May 15, 2008 at 9:00 a.m. EDT
4. Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results
5. Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors
6. Tianyin Pharmaceutical Co., Inc. Completes Production for Earthquake
7. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets
8. Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction
9. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets
10. Tianyin Pharmaceutical Co., Inc. Authorizes $3.0 Million Stock Repurchase Program
11. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 First Quarter Earnings Conference Call on Tuesday, November 11, 2008 at 8:30 a.m. EST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Newport Beach, Calif. (PRWEB) , ... April 29, 2016 , ... ... affect us. An effective way to confront and deal with these stressors is to ... taste bad to be good for you. Risa Groux, a certified Holistic Nutritionist and ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... more flexibility in repaying their loans, more information about their loan terms and ... total outstanding student loan debt, including federal and private loans, has reached $1.3 ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Spine Team ... pain, is proud to announce one of their physicians has been invited to be ... Physicians (Texas ACOFP) Family Practice Review conference on April 30, 2016. , Dr. ...
(Date:4/29/2016)... ON (PRWEB) , ... April 29, 2016 , ... ... and the Canadian Celiac Association (CCA), is pleased to announce the launch of ... gluten-free products, nutritional articles, recipes, and more. The purpose of the GFCP ...
(Date:4/29/2016)... ... , ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., a ... throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. , ... patented safety device secured by nasal surgeons onto the floor of the nasal passages, ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)... , April 28, 2016 ... "Global Plastic Surgery Products Market 2016-2020" report ... ) , The global plastic surgery ... of 9.47% during the period 2016-2020. , ,The growing ... leading to the growth of the market. Lasers are ...
(Date:4/28/2016)... 28, 2016 Treato , ... healthcare, announced today that it has been named a ... Vendor in Life Sciences, 2016, Stephen Davies ... report focuses on life-science- oriented analytics, algorithms and smart ... and doctors, confirm medication ingestion, and analyze unstructured information. ...
Breaking Medicine Technology: